WALTHAM - BostonGene, a leading provider of AI-driven, molecular and immune profiling solutions, and
This first-in-human study is being conducted at leading cancer institutions in the US and
'We partnered with BostonGene in order to validate theorized mechanisms of ADC efficacy and uncover novel biomarkers to improve patient selection as
'We are excited to collaborate with LCB to support the development of their novel, TROP2-directed ADC, LCB84, and to address the high unmet need in cancer for improved tumor targeting, safety and efficacy', said
Added Chief Medical Officer
BostonGene will serve as the study's central laboratory and analytic partner for exploratory biomarkers, performing in-depth, multi-omic profiling of patients' tumor tissue and blood samples, including whole-exome sequencing (WES), whole-transcriptome sequencing (RNAseq) of tumor tissue from matched tumor biopsies on the study, and immunoprofiling to identify hundreds of different cell types from a single blood sample. Leveraging its advanced AI and machine learning platforms, BostonGene will also deliver comprehensive analytics to identify predictive biomarkers and optimize the selection of patients most likely to benefit from treatment.
Each patient's tumor has a unique molecular 'fingerprint' that can be identified with BostonGene's differentiated analytic and software platforms for comprehensive, real-time, cost-efficient results to support the delivery of highly personalized cancer therapies that give patients the best chance of durable responses.
About
BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene's concierge-service model provides customized client solutions using a multi-omic approach prioritized for real-world impact to optimize standard-of-care therapies, accelerate research and provide cost-effective, measurable data-driven results. BostonGene's tests reveal key drivers of each patient's unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene's tests generate a personalized roadmap for therapeutic decision-making for each patient.
About
Contact:
Tel: +1-617-283-2285
Email: Erin.Oreilly@BostonGene.com
Tel: +82-42-861-0688
(C) 2023 Electronic News Publishing, source